Alexandria (ARE) Inks Leases at its Campuses Amid Solid Demand
https://www.zacks.com/stock/news/2200025/alexandria-are-inks-leases-at-its-campuses-amid-solid-demand?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2200025
Dec 19, 2023 - Amid the booming demand for life-science assets, Alexandria (ARE) inks leases with Novo Nordisk and CARGO at its mega campuses in Greater Boston and San Carlos in the San Francisco Bay Area.
0
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
https://www.zacks.com/stock/news/2200047/merck-mrk-gets-eu-nod-for-expanded-use-in-gastric-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200047
Dec 19, 2023 - Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.
0
FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab
https://www.zacks.com/stock/news/2200645/fda-accepts-merck-s-mrk-bla-for-21-valent-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200645
Dec 20, 2023 - The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.
0
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
https://www.zacks.com/stock/news/2200461/4-drug-stocks-rising-more-than-40-in-2023-with-room-to-grow?cid=CS-ZC-FT-analyst_blog|investment_ideas-2200461
Dec 20, 2023 - Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.
0
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals
https://www.zacks.com/stock/news/2201716/jazz-pharmaceuticals-jazz-ptsd-drug-misses-study-goals?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201716
Dec 22, 2023 - After a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug.
0
Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy
https://www.zacks.com/stock/news/2202279/sarepta-srpt-seeks-label-expansion-for-dmd-gene-therapy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202279
Dec 26, 2023 - Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.
0
Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now
https://www.zacks.com/stock/news/2205099/here-s-why-you-should-bet-on-rigel-pharmaceuticals-rigl-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2205099
Jan 03, 2024 - Here, we discuss some reasons why buying Rigel Pharmaceuticals (RIGL) stock now may turn out to be a prudent move.
0
Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal
https://www.zacks.com/stock/news/2207561/novo-nordisk-s-nvo-phase-iii-diabetes-study-meets-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207561
Jan 09, 2024 - Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.
0
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn
https://www.zacks.com/stock/news/2209026/c4-cccc-up-6-on-restructuring-plan-to-curb-cash-burn?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209026
Jan 11, 2024 - The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.
0
Novo Nordisk (NVO) Is Up 2.45% in One Week: What You Should Know
https://www.zacks.com/stock/news/2210353/novo-nordisk-nvo-is-up-2-45-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2210353
Jan 15, 2024 - Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
0